Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension

References

• Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Gu Q, Dillon CF, Burt VL, et al. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2010;23:38-45
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Kjeldsen SE, Mancia G. The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?. Am J Cardiovasc Drugs 2006;6:139-47
   PubMedGoogle Scholar
• Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:H1597-602
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin End Met 2001;86:713-18
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents?. Am J Hypertens 1998;11:1258-65
   PubMed Web of Science ®Google Scholar
• Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care 2004;27:247-55
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
   PubMed Web of Science ®Google Scholar
• Mason JM, Dickinson HO, Nicolson DJ, et al. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005;23:1777-81
   PubMed Web of Science ®Google Scholar
• Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006;29:1065-70
   PubMed Web of Science ®Google Scholar
• Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008;31:982-8
   PubMed Web of Science ®Google Scholar
• Padwal R, Mamdani M, Alter DA, et al. Antihypertensive therapy and incidence of type 2 diabetes in an elderly cohort. Diabetes Care 2004;27:2458-63
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shear E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9
   PubMed Web of Science ®Google Scholar
• Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997;277:739-45
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64
   PubMed Web of Science ®Google Scholar
• Bell DSH. Advantages of a third-generation β-blocker in patients with diabetes mellitus. Am J Cardiol 2004;93(Suppl.):49B-52B
   PubMedGoogle Scholar
• Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227-36
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol or Metoprolol European Trial (COMET). Heart 2007;93:968-73
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9 CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9 CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9
   PubMed Web of Science ®Google Scholar
• Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol–metoprolol study. J Hypertens 1996;14:489-94
   PubMed Web of Science ®Google Scholar
• Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized controlled trial. Ann Intern Med 1997;126:955-9
   PubMed Web of Science ®Google Scholar
• Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009;166:591-8
   PubMed Web of Science ®Google Scholar
• Ulcickas M, deLorenze G, Quesenberry CP Jr, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent – results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18:791-9
   PubMed Web of Science ®Google Scholar
• Data on file REF17672. GlaxoSmithKline
   Google Scholar
• López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on β-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004;25:1341-62
   PubMed Web of Science ®Google Scholar